A new publication dated August 28, 2026 presents a multicentre comparison of etelcalcetide and cinacalcet in hemodialysis patients with secondary hyperparathyroidism. The study, titled "Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up," appeared in the Journal of Clinical Medicine. The publication is identified by PubMed ID 42739661. The work reflects a 24-month follow-up period across multiple centers, according to the title. No specific findings, outcomes, or comparative results are detailed here beyond the publication announcement itself. Etelcalcetide is an approved therapy, and this publication adds to the body of literature examining its use relative to cinacalcet in this patient population. Readers interested in the clinical context of this comparison should consult the full text through the source link provided. This brief reports only the existence and bibliographic details of the publication as stated. No efficacy or safety conclusions are implied or should be inferred from this notice. For more background on etelcalcetide, readers can refer to the compound overview.
New Study Compares Etelcalcetide to Cinacalcet Over 24 Months
See the full etelcalcetide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42739661/